ML-225
Cognitive impairment in Alzheimer's Disease
PreclinicalTarget validation
Key Facts
Indication
Cognitive impairment in Alzheimer's Disease
Phase
Preclinical
Status
Target validation
Company
About MapLight Therapeutics
MapLight Therapeutics is focused on transforming the treatment of brain disorders by developing precision medicines that target specific dysfunctional neural circuits. The company's MAP (Molecular and Anatomical Phenotyping) platform integrates advanced neuroscience tools to deconstruct complex behaviors and identify novel therapeutic targets. With a lead program in Phase 2 for autism spectrum disorder and a pipeline of preclinical candidates, MapLight is advancing a new generation of neuropsychiatric drugs. The company went public in 2024 and is positioned to address significant unmet needs in neurology and psychiatry.
View full company profile